{
    "organizations": [],
    "uuid": "3de90a72c0b9426d4c8dd544985a537c5881c983",
    "author": "",
    "url": "https://www.reuters.com/article/brief-eisai-merck-receive-breakthrough-t/brief-eisai-merck-receive-breakthrough-therapy-designation-from-fda-for-lenvima-keytruda-idUSASB0C0B1",
    "ord_in_thread": 0,
    "title": "BRIEF-Eisai, Merck Receive Breakthrough Therapy Designation From FDA For Lenvima, Keytruda",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 03 PM / Updated 11 minutes ago BRIEF-Eisai, Merck Receive Breakthrough Therapy Designation From FDA For Lenvima, Keytruda Reuters Staff 1 Min Read \nJan 9 (Reuters) - Eisai Co Ltd: \n* EISAI AND MERCK RECEIVE BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR LENVIMA速 (LENVATINIB MESYLATE) AND KEYTRUDA速 (PEMBROLIZUMAB) AS COMBINATION THERAPY FOR ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA \n* EISAI AND MERCK RECEIVE BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR LENVIMA速 (LENVATINIB MESYLATE) AND KEYTRUDA速 (PEMBROLIZUMAB) AS COMBINATION THERAPY FOR ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA Source text for Eikon: Further company coverage:",
    "published": "2018-01-09T14:02:00.000+02:00",
    "crawled": "2018-01-09T14:20:08.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "merck",
        "receive",
        "breakthrough",
        "therapy",
        "designation",
        "fda",
        "lenvima",
        "keytruda",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "eisai",
        "co",
        "ltd",
        "eisai",
        "merck",
        "receive",
        "breakthrough",
        "therapy",
        "designation",
        "fda",
        "lenvatinib",
        "mesylate",
        "pembrolizumab",
        "combination",
        "therapy",
        "advanced",
        "metastatic",
        "renal",
        "cell",
        "carcinoma",
        "eisai",
        "merck",
        "receive",
        "breakthrough",
        "therapy",
        "designation",
        "fda",
        "lenvatinib",
        "mesylate",
        "pembrolizumab",
        "combination",
        "therapy",
        "advanced",
        "metastatic",
        "renal",
        "cell",
        "carcinoma",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}